Cabozantinib in the treatment of metastatic renal cell carcinoma – final data analysis from four oncology centers in the Czech Republic

Download PDF Česká verzia

Authors: I.- Richter ^{1 3}; A. Poprach ⁴; A. Zemánková ⁵; T. Büchler ²; J. Bartoš ¹; V. Šámal ⁶; H. Študentová ⁵; A. Rozsypalová ²; J. Dvořák ² ; O. Brom ⁷; B. Melichar ⁵
Authors place of work: Onkologické oddělení, KN Liberec, a. s. ¹; Onkologická klinika 1. LF UK a FTN Praha ²; Fakulta zdravotnických studií, TU Liberec ³; Klinika komplexní onkologické péče LF MU a MOÚ Brno ⁴; Onkologická klinika LF UP a FN Olomouc ⁵; Urologické oddělení, KN Liberec, a. s. ⁶; ACREA Česká republika ⁷
Published in the journal: Klin Onkol 2021; 34(5): 392-400
Category: Original Articles
doi: https://doi.org/10.48095/ccko2021392

Summary

Background: Current standard treatments for patients with metastatic renal cell carcinoma (mRCC) involve tyrosine kinase inhibitors (TKI) that inhibit angiogenesis. Cabozantinib is a multi TKI used for the treatment of mRCC in the first- and second-line setting. Purpose: The aim of this study was the final analysis of treatment outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with cabozantinib after previous targeted therapy. Patients and methods: A total of 54 patients with mRCC from four oncology centers in the Czech Republic were evaluated retrospectively; the median follow-up was 18.5 months. Cabozantinib was administered in a dose of 60 mg/day, a subset of patients received an initial dose of 40 mg/day. The treatment was administered until the progression. The Kaplan-Meier analysis was used to calculate progression free survival (PFS) and overall survival (OS). We performed a multivariate analysis of risk factors for treatment outcomes (PFS, OS) by regression analysis. All statistics were evaluated at the significance level α = 0.05. Results: The median PFS in all patients was 9.3 months (95% CI 7.2 – 11.4). The median OS in all patients was 21.9 months (95% CI 15.5 – 28.4). The median PFS in patients with bone metastases was not statistically significantly different compared with patients without bone metastases (9.3 vs 8.7 months, P = 0.53). The median OS in patients with bone metastases was statistically significantly shorter compared with patients without bone metastases (17.7 vs 26.8 months, P = 0.021). A treatment response was observed in 40.7 % of cases, including one complete remission. The regression analysis demonstrated a significant effect on OS in patients with the presence of subsequent treatment (P = 0.001), patients with treatment duration of first line therapy ≥ 6 months (P = 0.019) and ≥ 12 months (P = 0.003) and in patients without bone metastases (P = 0.021). Conclusion: Our final analysis of patients with mRCC treated with cabozantinib after previous targeted therapy confirmed its effectiveness.

Keywords:

renal carcinoma – metastases – cabozantinib – targeted treatment – treatment results

Zdroje

1. Dušek L, Mužík J, Kubásek M et al. Epidemiologie zhoubných nádorů v České republice. Brno: Masarykova univerzita 2007.

2. Marenčák J, Ondrušová M, Ondruš D. Recent overview of kidney cancer diagnostics and treatment. Klin Onkol 2017; 30 (3): 175–181. doi: 10.14735/amko2017175.

3. Richter I, Dvořák J. Treatment of metastatic renal cell carcinoma. Klin Onkol 2018; 31 (2): 110–116. doi: 10.14735/amko2018110.

4. Kaelin WG Jr. The von Hippel-Lindau tumour suppressors protein: O2 sensing and cancer. Nat Rev Cancer 2008; 8 (11): 865–873. doi: 10.1038/nrc2502.

5. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Eng J Med 2007; 356 (2): 115–124. doi: 10.1056/NEJMoa065044.

6. Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27 (22): 3584–3590. doi: 10.1200/JCO.2008.20.1293.

7. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28 (6): 1061–1068. doi: 10.1200/JCO.2009.23.9764.

8. Motzer RJ, Hutson TE, Cella D et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013; 369 (8): 722–731. doi: 10.1056/NEJMoa1303 989.

9. Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27 (20): 3312–3318. doi: 10.1200/JCO.2008.19. 5511.

10. Motzer RJ, Escudier B, Tomczak P et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013; 14 (6): 552–562. doi: 10.1016/S1470-2045 (13) 70 093-7.

11. Escudier B, Bellmunt J, Négrier S et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010; 28 (13): 2144–2150. doi: 10.1200/JCO.2009.26.7849.

12. Poprach A, Fiala O, Chloupková R et al. Pazopanib for metastatic renal cell carcinoma: a registry-based analysis of 426 patients. Anticancer Res 2018; 38 (1): 449–456. doi: 10.21873/anticanres.12243.

13. Poprach A, Bortlíček Z, Büchler T et al. Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database. Med Oncol 2012; 29 (5): 3314–3320. doi: 10.1007/s12032-012-02 86-9.

14. Motzer RJ, Escudier B, McDermott DF et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373 (19): 1903–1813. doi: 10.1056/ NEJMoa1510665.

15. Motzer RJ, Tannir NM, McDermott DF et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018; 378 (14): 1277–1299. doi: 10.1056/NEJMoa1712126.

16. Motzer RJ, Penkov K, Haanen J et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Eng J Med 2019; 380 (12): 1103–1115. doi: 10.1056/NEJMoa1816047.

17. Rini BI, Plimack ER, Stus V et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Eng J Med 2019; 380 (12): 1116–1127. doi: 10.1056/NEJMoa1816714.

18. Büchler T. Imunoterapie renálního karcinomu. Klin Onkol 2015; 28 (Suppl 4): 64–68. doi: 10.14735/amko20154S64.

19. Yakes FM, Chen J, Tan J et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresse metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011; 10 (12): 2298–2308. doi: 10.1158/1535-7163.MCT-11-0264.

20. Tannir NM, Schwab G, Grunwald V. Cabozantinib: an active novel multikinase inhibitor in renal cell carcinoma. Curr Oncol Rep 2017; 19 (2): 14. doi: 10.1007/s11912-017-0566-9.

21. Zhou L, Liu XD, Sun M et al. Targeting MET and AXL overcomes resistence to sunitinib therapy in renal cell carcinoma. Oncogene 2016; 35 (21): 2687–2697. doi: 10.1038/onc.2015.343.

22. Choueiri TK, Escudier B, Powles T et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373 (19): 1814–1823. doi: 10.1056/ NEJMoa1510016.

23. Richter I, Poprach A, Zemankova A et al. Patients with metastatic renal cell cancer treated with cabozantinib in the Czech Republic: analysis of four cancer centers. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2020. doi: 10.5507/bp.2020.055.

24. Bodnar L, Kopczyńska A, Zolnierek J et al. Real-world experience of cabozantinib as second- or subsequent line treatment in patients with metastatic renal cell carcinoma: data from the Polish managed access program. Clin Genitourine Cancer 2019; 17 (3): e556–e564. doi: 10.1016/j.clgc.2019.02.002.

25. Procopio G, Priscinadaro M, Iacovelli R et al. Safety and efficacy of cabozantinib in metastatic renal-cell carcinoma: real-world data from an Italian managed access program. Clin Genitourinal Cancer 2018; 16 (4): e945–e951. doi: 10.1016/j.clgc.2018.03.014.

26. McKay RR, Kroeger N, Xie W et al. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol 2014; 65 (3): 577–584. doi: 10.1016/j.eururo.2013.08.012.

27. Beuselinck B, Oudard S, Rixe O et al. Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol 2011; 22 (4): 794–800. doi: 10.1093/annonc/mdq554.

28. Dai J, Zhang H, Karatsinides A et al. Cabozantinib inhibits prostate cancer growth and prevents tumor – induced bone lesions. Clin Cancer Res 2014; 20 (3): 617–630. doi: 10.1158/1078-0432.CCR-13-0839.

29. Escudier B, Powles T, Motzer RJ et al. Cabozantinib, a new standard of care for patients with advanced renal cell carcinoma and bone metastases? Subgroup analysis of the METEOR trial. J Clin Oncol 2018; 36 (8): 765–772. doi: 10.1200/JCO.2017.74.7352.

30. Choueiri TK, Halabi S, Sanford BL et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J Clin Oncol 2017; 35 (6): 591–597. doi: 10.1200/JCO.2016.70.7398.

31. George DJ, Hessel C, Halabi S et al. Cabozantinib versus sunitinib for untreated patients with advanced renal cell carcinoma of intermediate or poor risk: subgroup analysis of the alliance A031203 CABOSUN trial. Oncologist 2019; 24 (11): 1497–1501. doi: 10.1634/theoncologist.2019-0316.

32. Choueiri TK, Powles T, Burotto M et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2021; 384 (9): 829–841. doi: 10.1056/NEJMoa2026982.